Recovery of antiviral immune responses after iC9-T-cell infusion and administration of AP1903. Patients 1 (A-B), 2 (C-D), and 5 (E-F) had viral reactivation and also received AP1903 to control acute GvHD. Left panels (A,C-D) illustrate the viral load for each single patient at multiple times; right panels (B,D-F) illustrate the quantification of pathogen-specific T cells detected either by IFN-γ ELIspot or intracellular staining in the CD3⁺CD19⁺ and CD3⁺CD19⁻ T cells at each time.